Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway

Journal of Neuroimmune Pharmacology

Volumn 9, Issue 3, 2014, Pages 380-387

  Chen, Lei Lei ^a   Song, Ju Xian ^a   Lu, Jia Hong ^a,b   Yuan, Zhen Wei ^a   Liu, Liang Feng ^a   Durairajan, Siva Sundara Kumar ^a   Li, Min ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha synuclein; autophagy; Corynoxine; mTOR; Parkinson's disease

Indexed keywords

ALKALOID DERIVATIVE; ALPHA SYNUCLEIN; C 13002; CATHEPSIN D; CORYNOXINE; LYSOSOME ENZYME; MAMMALIAN TARGET OF RAPAMYCIN; OXINDOLE; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG; ALKALOID; CORYNOXEINE; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL LINE; CHINESE MEDICINE; CONTROLLED STUDY; DROSOPHILA; DRUG MECHANISM; ENANTIOMER; FAT BODY; HERBAL MEDICINE; IN VIVO STUDY; NERVE CELL; NONHUMAN; PC12 CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; ANIMAL; DRUG EFFECTS; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN TRANSPORT; TRANSGENIC ANIMAL; TUMOR CELL LINE;

ALKALOIDS; ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; AUTOPHAGY; CELL LINE, TUMOR; DROSOPHILA; HUMANS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; TOR SERINE-THREONINE KINASES;

EID: 84901263861     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-014-9528-2     Document Type: Article

References (38)

1. Cannon JR, Geghman KD, Tapias V, Sew T, DailMK, Li C, Greenamyre JT (2013) Expression of human E46K-mutated alpha-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. Exp Neurol 240:44-56
2. Cullen V, Lindfors M, Ng J, Paetau A, Swinton E, Kolodziej P, Boston H, Saftig P,Woulfe J, Feany MB, Myllykangas L, SchlossmacherMG, Tyynela J (2009) Cathepsin D expression level affects alphasynuclein processing, aggregation, and toxicity in vivo. Mol Brain 2:5
3. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson's disease. Lancet Neurol 5:525-535 (Pubitemid 44262284)
4. Febbraro F, Sahin G, Farran A, Soares S, Jensen PH, Kirik D, Romero-Ramos M (2013) Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. Neurobiol Dis 56C:47-58
5. Floto RA, Sarkar S, Perlstein EO, Kampmann B, Schreiber SL, Rubinsztein DC (2007) Small molecule enhancers of rapamycininduced TOR inhibition promote autophagy, reduce toxicity in Huntington's disease models and enhance killing of mycobacteria by macrophages. Autophagy 3:620-622 (Pubitemid 350060063)
6. Jung CH, Ro SH, Cao J, Otto NM, Kim DH (2010) mTOR regulation of autophagy. FEBS Lett 584:1287-1295
7. Knight SD, Adams ND, Burgess JL, Chaudhari AM, Darcy MG, Donatelli CA, Luengo JI, Newlander KA, Parrish CA, Ridgers LH, Sarpong MA, Schmidt SJ, Van Aller GS, Carson JD, Diamond MA, Elkins PA, Gardiner CM, Garver E, Gilbert SA, Gontarek RR, Jackson JR, Kershner KL, Luo LS, Raha K, Sherk CS, Sung CM, Sutton D, Tummino PJ, Wegrzyn RJ, Auger KR, Dhanak D (2010) Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. Acs Med Chem Lett 1:39-43
8. Kum WF, Durairajan SS, Bian ZX, Man SC, Lam YC, Xie LX, Lu JH, Wang Y, Huang XZ, Li M (2011) Treatment of idiopathic Parkinson's disease with traditional chinese herbal medicine: a randomized placebo-controlled pilot clinical study. Evid Based Complement Alternat Med 2011:724353
9. Lashuel HA, Overk CR, Oueslati A,Masliah E (2013) The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 14:38-48
10. Li XJ, Li H, Li S (2010) Clearance of mutant huntingtin. Autophagy 6
11. Lo Bianco C, Ridet JL, Schneider BL, Deglon N, Aebischer P (2002) alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci 99:10813-10818
12. Lohar MV, Mundada R, Bhonde M, Padgaonkar A, Deore V, Yewalkar N, Bhatia D, Rathos M, Joshi K, Vishwakarma RA, Kumar S (2008) Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway. Bioorg Med Chem Lett 18:3603-3606 (Pubitemid 351787555)
13. Lu JH, Tan JQ, Durairajan SS, Liu LF, Zhang ZH, Ma L, ShenHM, Chan HY, Li M (2012) Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. Autophagy 8:98-108
14. Lynch-Day MA, Mao K,Wang K, ZhaoM, Klionsky DJ (2012) The role of autophagy in Parkinson's disease. Cold Spring Harb Perspect Med 2:a009357
15. Malagelada C, Jin ZH, Jackson-Lewis V, Przedborski S, Greene LA (2010) Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci 30:1166-1175
16. Mizuno H, Fujikake N, Wada K, Nagai Y (2010) alpha-Synuclein Transgenic Drosophila As a Model of Parkinson's Disease and Related Synucleinopathies. Parkinsons Dis 2011:212706.
17. Qi L, Zhang XD,Wu JC, Lin F,Wang J, DiFiglia M, Qin ZH (2012) The role of chaperone-mediated autophagy in huntingtin degradation. PLoS One 7:e46834
18. Recchia A, Debetto P, Negro A, Guidolin D, Skaper SD, Giusti P (2004) Alpha-synuclein and Parkinson's disease. FASEB J 18:617-626
19. Salminen A, Kaarniranta K, Kauppinen A, Ojala J, Haapasalo A, Soininen H, Hiltunen M (2013) Impaired autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome. Prog Neurobiol 106-107:33-54
20. Santos RX, Correia SC, Cardoso S, Carvalho C, Santos MS, Moreira PI (2011) Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease. J Neurochem 117(6):927-936
21. Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL, Webster JA, Lewis TA, O'Kane CJ, Schreiber SL, Rubinsztein DC (2007) Small molecules enhance autophagy and reduce toxicity in Huntington 's disease models. Nat Chem Biol 3(6):331-338 (Pubitemid 46789270)
22. Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, Rubinsztein DC (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 17:170-178
23. Scott RC, Schuldiner O, Neufeld TP (2004) Role and regulation of starvation-induced autophagy in the Drosophila fat body. Dev Cell 7:167-178 (Pubitemid 39145023)
24. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V (2010) Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 5:e9979
25. Suk K, Kim SY, Leem K, Kim YO, Park SY, Hur J, Baek J, Lee KJ, Zheng HZ, Kim H (2002) Neuroprotection by methanol extract of Uncaria rhynchophylla against global cerebral ischemia in rats. Life Sci 70:2467-2480 (Pubitemid 34267036)
26. Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ (2009) Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 12:1129-1135
27. Tang NY, Liu CH, Su SY, Jan YM, Hsieh CT, Cheng CY, Shyu WC, Hsieh CL (2010) Uncaria rhynchophylla (miq) Jack plays a role in neuronal protection in kainic acid-treated rats. Am J Chin Med 38: 251-263
28. Tsvetkov AS, Miller J, Arrasate M, Wong JS, Pleiss MA, Finkbeiner S (2010) A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. Proc Natl Acad Sci 107:16982-16987
29. Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC (2003) Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 278:25009-25013 (Pubitemid 37548663)
30. Wolfe DM, Lee JH, Kumar A, Lee S, Orenstein SJ, Nixon RA (2013) Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. Eur J Neurosci 37:1949-1961
31. Xu Y, Kim SO, Li Y, Han J (2006) Autophagy contributes to caspase-independent macrophage cell death. J Biol Chem 281:19179-19187 (Pubitemid 44035422)
32. Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H (2004) Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 91:451-461 (Pubitemid 39363444)
33. Yang J, Shamji A, Matchacheep S, Schreiber SL (2007) Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening. Chem Biol 14:371-377 (Pubitemid 46617312)
34. Yelamanchili SV, Chaudhuri AD, Flynn CT, Fox HS (2011) Upregulation of cathepsin D in the caudate nucleus of primates with experimental parkinsonism. Mol Neurodegener 6:52
35. Yuan H, Perry CN, Huang C, Iwai-Kanai E, Carreira RS, Glembotski CC, Gottlieb RA (2009) LPS-induced autophagy is mediated by oxidative signaling in cardiomyocytes and is associated with cytoprotection. Am J Physiol Heart Circ Physiol 296:470-479
36. Zavala JA, Munhoz RP, Teive HA (2012) Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease. J Clin Neurosci 19:1298-1299
37. Zhang YJ, Duan Y, Zheng XF (2011) Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today 16:325-331
38. Zunder ER, Knight ZA, Houseman BT, Apsel B, Shokat KM (2008) Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell 14:180-192